CSPC Pharma's SYH2046 tablets receive China trial approval

CSPC Pharmaceutical Group Limited (HKEX: 1093) announced that its SYH2046 Tablets have received clinical trial approval from China's National Medical Products Administration. The drug, a first-in-class small molecule treatment, targets heart failure following acute myocardial infarction. Preclinical studies have indicated the Product's potential to improve cardiac function and reduce adverse cardiac remodeling, with an improved safety profile. Acute myocardial infarction is a significant contributor to heart failure, with incidence rates ranging from 14% to 36% and a five-year mortality rate of 42.3% for hospitalized patients. The Company emphasizes that the new drug candidate offers a novel mechanism of action aimed at promoting tissue repair and restoring cardiac function, potentially providing a clinical development value compared to current medications.